PMI
13.6.2019 12:39:03 CEST | Business Wire | Press release
Philip Morris International (PMI) today launches unsmokeyourworld.com , a new online hub for those that want to un smoke themselves or their loved ones, their communities, or the world. The website aims to provide an inspiring and engaging place to help people kick-start their smoke-free journeys. The best way to un smoke is to quit cigarettes and nicotine completely. For adult smokers that don’t the next best option is to switch to a better alternative.
A new survey conducted by Povaddo, commissioned by PMI, shows the potential to improve personal and social relationships by quitting cigarettes. Almost three-quarters—71 percent—of nonsmokers who are in a relationship with a smoking partner said they have had disagreements with their partner because he/she smokes cigarettes. The results showed even higher levels of disagreement in Israel, Italy and Russia, with 80 percent or more stating they have argued with their partner over smoking.
| Have you ever had a disagreement or argument with your partner or spouse because he/she smokes cigarettes? | |||||||||||||
|
Yes |
Russia | U.K. | U.S. | Hong Kong | Israel | Italy | |||||||
| 82% | 63% | 63% | 67% | 80% | 87% | ||||||||
| Japan | Mexico | Australia | Brazil | Denmark | Germany | ||||||||
| 55% | 77% | 68% | 72% | 56% | 55% | ||||||||
| Base: former and never smokers with a partner that smokes | |||||||||||||
Smokers, however, were less likely to recognize the impact that smoking has on their relationships with loved ones, with just, on average, 36 percent of them acknowledging that smoking has caused arguments with their loved ones.
| My smoking causes arguments with loved ones: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Strongly/ Somewhat agree | Russia | U.K. | U.S. | Hong Kong | Israel | Italy | |||||||||||||||||||||||||||||||||||||||||||||||||
| 38% | 32% | 32% | 42% | 43% | 43% | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Japan | Mexico | Australia | Brazil | Denmark | Germany | ||||||||||||||||||||||||||||||||||||||||||||||||||
| 22% | 43% | 25% | 62% | 8% | 22% | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
Base: current and occasional smokers.
Figures have been summed due to rounding |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
“This research shows the scale of the task ahead to help smokers understand the positive impact that unsmoking could have on their relationships,” said Jacek Olczak, Chief Operating Officer, PMI. “We believe that this type of insight should be made known to smokers so they can engage in a conversation and understand the benefits of getting behind the #unsmoke movement.”
Aiming to unify communities toward a smoke-free world, PMI’s unsmokeyourworld.com is an online hub where adult smokers and those that care about them can discover more about ways to un smoke. The site shares stories of un smoke heroes describing their smoke-free journeys and encourages readers to share their own stories.
Olczak continues: “Change comes from communities uniting behind a positive conversation, which is why we have created this place for people to come together and hear each other’s stories for inspiration. This is an important new tool for adult smokers and those who care about them so they can access resources to inspire them to leave cigarettes behind.”
Interactive elements engage readers to understand the facts behind unsmoking and allows them to publicly get involved. Users can add an ‘Un smoke Your World’ overlay to any image they want so they can show support on social media. They can also download and share a selection of gifs to celebrate un smoke successes.
Since April 2019, over 115,000 digital #unsmokeyourworld actions have taken place across the globe—ranging from individuals supporting the campaign on social media to engaging with digital content. PMI’s is calling for people to take action and create a strong movement to an un smoked world. For more information visit, unsmokeyourworld.com .
About the Povaddo Survey
This survey was carried out 24
April-6 May, 2019, by Povaddo, a leading public opinion research firm,
on behalf of Philip Morris International. The survey fielded a total of
16,099 online interviews among general population adults 21-74 years of
age across 13 countries (Argentina, Australia, Brazil, Denmark, Germany,
Hong Kong, Israel, Italy, Japan, Mexico, Russia, United Kingdom and
United States). The survey carries an overall margin of error of +/- 1%
at the 95 percent confidence interval.
About #Unsmokeyourworld
PMI is transforming its business and
increasing awareness of the urgent need to become smoke-free as well as
awareness of better alternatives for smokers who would otherwise
continue to smoke. PMI is producing smoke-free products that are a
better choice for smokers than continued cigarette smoking and can
benefit public health.
#Unsmoke is a PMI initiative to speed up an historic change in public health. Through the #unsmoke movement, we want to bring together a community of people who can accelerate this change by becoming advocates of the message that for smokers who would otherwise continue to smoke, there are better alternatives to choose from.
#Unsmokeyourworld is a global conversation that inspires human stories—for the people, by the people.
About Philip Morris International
Delivering a Smoke-Free
Future Philip Morris International (PMI) is leading a transformation in
the tobacco industry to create a smoke-free future and ultimately
replace cigarettes with smoke-free products to the benefit of adults who
would otherwise continue to smoke, society, the company and its
shareholders. PMI is a leading international tobacco company engaged in
the manufacture and sale of cigarettes, smoke-free products and
associated electronic devices and accessories, and other
nicotine-containing products in markets outside the U.S. PMI is building
a future on a new category of smoke-free products that, while not
risk-free, are a much better choice than continuing to smoke. Through
multidisciplinary capabilities in product development, state-of-the-art
facilities and scientific substantiation, PMI aims to ensure that its
smoke-free products meet adult consumer preferences and rigorous
regulatory requirements. For more information, please visit http://www.pmi.com
and www.pmiscience.com
.
# # #
View source version on businesswire.com: https://www.businesswire.com/news/home/20190613005304/en/
Contact:
David Fraser Philip Morris International Media Office T. +41 (0)58 242 4500 E. david.fraser@pmi.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
